Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.
In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet needs in ATTR-CM. He reviews existing silencer therapy data and examines the CARDIO-TTRansform study design and baseline population in greater detail, highlighting how these findings may influence future management strategies.
In the second part, Dr Maurer is joined by Dr Margot Davis (University of British Columbia, Vancouver, CA) for an expert peer-to-peer discussion placing the data into broader clinical context. Together, they explore:
- The potential impact of CARDIO-TTRansform on future clinical practice
- The evolving treatment landscape for silencer therapies in ATTR-CM
- Mechanistic differences between emerging silencer approaches
- Remaining unmet needs and gaps in current guideline recommendations
- The role of real-world evidence in shaping future practice
Whether you are looking for a detailed review of the data or an understanding of clinical perspectives, this series provides valuable insight into the latest developments in ATTR-CM and their relevance to patient care.
Key Learning Objectives
- Recall unique trial design features of CARDIO-TTRansform including NT-proBNP criteria, open-label concomitant stabiliser use, and primary endpoint
- Describe key patient baseline results of the CARDIO-TTRansform population including number of participants, proportion already on stabiliser therapy and proportion of participants with V122I genotype
- Compare baseline characteritics with other contemporary ATTR RCTs
- Describe the severity of heart failure and ATTR-CM severity at baseline in the context of other ATTR RCTs
Target Audience
- Heart Failure Specialists
- Cardiologists
- Nephrologists
More from this programme
Part 1
A Deep Dive Into the Data: CARDIO-TTRansform Design and Baseline Characteristics
Dr Maurer takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet needs in ATTR-CM. He reviews existing silencer therapy data and examines the CARDIO-TTRansform study design and baseline population, highlighting how these findings may influence future management strategies.
Part 2
In Context: A Peer-To-Peer Discussion on CARDIO-TTRansform and Other Emerging Data
Dr Davis and Dr Maurer discuss CARDIO-TTRansform and other emerging data into broader clinical context. They explore the evolving treatment landscape for silencer therapies in ATTR-CM, mechanistic differences between emerging silencer approaches and the role of real-world evidence in shaping future practice.
Faculty Biographies
Mathew S Maurer
Arnold and Arlene Goldstein Professor of Cardiology
Dr Mathew S Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus. He is the Director of the Cardiac Amyloidosis Program.
He has published over 300 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organisation dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for…
Comments